JP6771469B2 - 駆虫性化合物、組成物及びこれらの使用方法 - Google Patents

駆虫性化合物、組成物及びこれらの使用方法 Download PDF

Info

Publication number
JP6771469B2
JP6771469B2 JP2017538327A JP2017538327A JP6771469B2 JP 6771469 B2 JP6771469 B2 JP 6771469B2 JP 2017538327 A JP2017538327 A JP 2017538327A JP 2017538327 A JP2017538327 A JP 2017538327A JP 6771469 B2 JP6771469 B2 JP 6771469B2
Authority
JP
Japan
Prior art keywords
diyl
group
formula
alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017538327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502877A (ja
JP2018502877A5 (enExample
Inventor
アラン ロング
アラン ロング
ダグラス エドワード ウィルキンソン
ダグラス エドワード ウィルキンソン
Original Assignee
ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド
ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド, ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド filed Critical ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド
Publication of JP2018502877A publication Critical patent/JP2018502877A/ja
Publication of JP2018502877A5 publication Critical patent/JP2018502877A5/ja
Application granted granted Critical
Publication of JP6771469B2 publication Critical patent/JP6771469B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2017538327A 2015-01-20 2016-01-20 駆虫性化合物、組成物及びこれらの使用方法 Expired - Fee Related JP6771469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105463P 2015-01-20 2015-01-20
US62/105,463 2015-01-20
PCT/US2016/014148 WO2016118638A1 (en) 2015-01-20 2016-01-20 Anthelmintic compounds, compositions and method of using thereof

Publications (3)

Publication Number Publication Date
JP2018502877A JP2018502877A (ja) 2018-02-01
JP2018502877A5 JP2018502877A5 (enExample) 2019-02-21
JP6771469B2 true JP6771469B2 (ja) 2020-10-21

Family

ID=55299781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017538327A Expired - Fee Related JP6771469B2 (ja) 2015-01-20 2016-01-20 駆虫性化合物、組成物及びこれらの使用方法

Country Status (11)

Country Link
US (1) US10597364B2 (enExample)
EP (1) EP3247701B1 (enExample)
JP (1) JP6771469B2 (enExample)
CN (1) CN107257793A (enExample)
AU (3) AU2016209321B2 (enExample)
BR (1) BR112017015273A2 (enExample)
CA (1) CA2973873A1 (enExample)
ES (1) ES2907461T3 (enExample)
MX (1) MX379304B (enExample)
NZ (1) NZ734082A (enExample)
WO (1) WO2016118638A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CA3026512A1 (en) 2016-06-13 2017-12-21 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
HUE057328T2 (hu) 2016-07-20 2022-05-28 Novartis Ag Aminopiridin származékok és szelektív ALK-2 gátlóként való alkalmazásuk
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
SG10202002990XA (en) 2017-08-04 2020-05-28 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
RS64759B1 (sr) 2018-07-10 2023-11-30 Novartis Ag 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-dion derivati i njihova primena u lečenju bolesti zavisnih od cink prsta 2 (ikzf2) iz porodice ikaros
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR116524A1 (es) * 2018-10-04 2021-05-19 Elanco Tiergesundheit Ag Potenciación de tratamiento de helmintos
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
GB201820626D0 (en) * 2018-12-18 2019-01-30 Univ Of Canterbury Conjugates
LT3911647T (lt) 2019-01-15 2024-03-25 Gilead Sciences, Inc. Izoksazolo junginys kaip fxr agonistas ir jį apimančios farmacinės kompozicijos
EP3911640A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2020191091A1 (en) * 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
EP4048664A1 (en) 2019-10-25 2022-08-31 Gilead Sciences, Inc. Glp-1r modulating compounds
CR20220280A (es) 2019-11-22 2022-09-02 Incyte Corp Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
PL4097097T3 (pl) 2020-01-29 2025-05-12 Gilead Sciences, Inc. Związki modulujące glp-1r
EP4149941B1 (en) 2020-05-15 2025-09-03 Algen Biotechnologies, Inc. Certain chemical compositions and methods of use thereof
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
US12180197B2 (en) 2021-03-11 2024-12-31 Gilead Sciences, Inc. GLP-1R modulating compounds
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
AU2022263410B2 (en) 2021-04-21 2024-08-01 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
AU1631699A (en) 1997-12-18 1999-07-05 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
WO2001054503A1 (en) 2000-01-28 2001-08-02 Akkadix Corporation Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
CA2542031A1 (en) * 2003-10-10 2005-04-21 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
ES2505090T3 (es) * 2004-05-07 2014-10-09 Amgen Inc. Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer
DE102005032838A1 (de) * 2005-07-14 2007-02-08 Merck Patent Gmbh Mischung von Onium-Alkylsulfonaten und Onium-Alkylsulfiten
JPWO2007063839A1 (ja) * 2005-11-30 2009-05-07 塩野義製薬株式会社 シクロヘキサン誘導体
TW200938203A (en) 2007-12-17 2009-09-16 Intervet Int Bv Anthelmintic agents and their use
TW201041868A (en) * 2009-03-20 2010-12-01 Intervet Int Bv Anthelmintic agents and their use
TW201111358A (en) 2009-06-18 2011-04-01 Intervet Int Bv Anthelmintic agents and their use
JP2013507366A (ja) 2009-10-09 2013-03-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性モジュレーターとしての化合物および組成物
JP2013526546A (ja) * 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
AU2011253058A1 (en) * 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
EP2468096A1 (en) 2010-12-21 2012-06-27 Intervet International BV Anthelmintic combinations
US8530461B2 (en) * 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
JP6233855B2 (ja) * 2012-08-08 2017-11-22 ノバルティス・ティーアゲズントハイト・アクチェンゲゼルシャフトＮｏｖａｒｔｉｓ Ｔｉｅｒｇｅｓｕｎｄｈｅｉｔ Ａｇ 殺虫剤としての置換されたアジン類
AU2013348175B2 (en) * 2012-11-20 2016-11-17 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds and compositions and method of using thereof
AU2014244555B2 (en) * 2013-03-12 2018-06-28 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
CN105960401B (zh) 2013-11-18 2018-06-08 瑞士伊兰科动物保健有限公司 吡啶基或嘧啶基化合物
CA2949511A1 (en) 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds

Also Published As

Publication number Publication date
JP2018502877A (ja) 2018-02-01
AU2020204400A1 (en) 2020-07-30
EP3247701B1 (en) 2021-09-22
AU2019202773A1 (en) 2019-05-16
CN107257793A (zh) 2017-10-17
CA2973873A1 (en) 2016-07-28
EP3247701A1 (en) 2017-11-29
US10597364B2 (en) 2020-03-24
US20180009754A1 (en) 2018-01-11
WO2016118638A1 (en) 2016-07-28
BR112017015273A2 (pt) 2018-01-09
MX2017009408A (es) 2017-10-02
NZ734082A (en) 2019-01-25
AU2016209321A1 (en) 2017-08-17
MX379304B (es) 2025-03-11
AU2019202773B2 (en) 2020-07-02
ES2907461T3 (es) 2022-04-25
AU2016209321B2 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
JP6771469B2 (ja) 駆虫性化合物、組成物及びこれらの使用方法
KR102151832B1 (ko) 구충제 화합물 및 조성물 및 이의 사용 방법
ES2842592T3 (es) Compuestos antihelmínticos
AU2018205137B2 (en) Long-acting injectable formulations comprising an isoxazoline active agent, methods and uses thereof
JP6619756B2 (ja) インドール誘導体を含む殺寄生虫性組成物、寄生虫駆除方法及びこれらの使用
OA17714A (en) Anthelmintic compounds and compositions and method of using thereof.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200107

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20200107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200805

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200805

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200813

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200923

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200929

R150 Certificate of patent or registration of utility model

Ref document number: 6771469

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees